404 related articles for article (PubMed ID: 10709142)
1. 5-Aminosalicylic acid containing drugs. Delivery, fate, and possible clinical implications in man.
Christensen LA
Dan Med Bull; 2000 Feb; 47(1):20-41. PubMed ID: 10709142
[TBL] [Abstract][Full Text] [Related]
2. 5-Aminosalicylic acid derivatives. Clinical and pharmaceutical evaluation.
Christensen LA; Jacobsen BA
Neth J Med; 1989 Jun; 35 Suppl 1():S3-10. PubMed ID: 2702310
[TBL] [Abstract][Full Text] [Related]
3. Topical and systemic availability of 5-aminosalicylate: comparisons of three controlled release preparations in man.
Christensen LA; Fallingborg J; Abildgaard K; Jacobsen BA; Sanchez G; Hansen SH; Bondesen S; Hvidberg EF; Rasmussen SN
Aliment Pharmacol Ther; 1990 Oct; 4(5):523-33. PubMed ID: 2129640
[TBL] [Abstract][Full Text] [Related]
4. Bioavailability of controlled release mesalazine (5-ASA) preparations.
Rasmussen SN
J Gastroenterol; 1995 Nov; 30 Suppl 8():112-4. PubMed ID: 8563869
[TBL] [Abstract][Full Text] [Related]
5. Oral mesalazine for the treatment of Crohn's disease: clinical efficacy with respect to pharmacokinetic properties.
Tromm A; Griga T; May B
Hepatogastroenterology; 1999; 46(30):3124-35. PubMed ID: 10626173
[TBL] [Abstract][Full Text] [Related]
6. Systemic uptake of 5-aminosalicylic acid from olsalazine and eudragit L coated mesalazine in patients with ulcerative colitis in remission.
Ewe K; Becker K; Ueberschaer B
Z Gastroenterol; 1996 Apr; 34(4):225-9. PubMed ID: 8686349
[TBL] [Abstract][Full Text] [Related]
7. Comparative bioavailability of 5-aminosalicylic acid from a controlled release preparation and an azo-bond preparation.
Christensen LA; Fallingborg J; Jacobsen BA; Abildgaard K; Rasmussen HH; Hansen SH; Rasmussen SN
Aliment Pharmacol Ther; 1994 Jun; 8(3):289-94. PubMed ID: 7918923
[TBL] [Abstract][Full Text] [Related]
8. A clinical trial on absorption and N-acetylation of oral and rectal mesalazine.
Dilger K; Trenk D; Rössle M; Cap M; Zähringer A; Wacheck V; Remmler C; Cascorbi I; Kreisel W; Novacek G
Eur J Clin Invest; 2007 Jul; 37(7):558-65. PubMed ID: 17576207
[TBL] [Abstract][Full Text] [Related]
9. New oral salicylates in the therapy of chronic idiopathic inflammatory bowel disease.
Robinson MG
Gastroenterol Clin North Am; 1989 Mar; 18(1):43-50. PubMed ID: 2646221
[TBL] [Abstract][Full Text] [Related]
10. A novel dissolution method relevant to intestinal release behaviour and its application in the evaluation of modified release mesalazine products.
Schellekens RC; Stuurman FE; van der Weert FH; Kosterink JG; Frijlink HW
Eur J Pharm Sci; 2007 Jan; 30(1):15-20. PubMed ID: 17085024
[TBL] [Abstract][Full Text] [Related]
11. A dynamic model of colonic concentrations of delayed-release 5-aminosalicylic acid (Asacol).
Thorpe MP; Ehrenpreis ED; Putt KS; Hannon B
Aliment Pharmacol Ther; 2009 Jun; 29(11):1193-201. PubMed ID: 19222409
[TBL] [Abstract][Full Text] [Related]
12. Ulcerative colitis therapy: importance of delivery mechanisms.
Rochester J; Abreu MT
Rev Gastroenterol Disord; 2005; 5(4):215-22. PubMed ID: 16369217
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of 5-aminosalicyltaurine as a colon-specific prodrug of 5-aminosalicylic acid for treatment of experimental colitis.
Jung Y; Kim HH; Kim H; Kong H; Choi B; Yang Y; Kim Y
Eur J Pharm Sci; 2006 May; 28(1-2):26-33. PubMed ID: 16455235
[TBL] [Abstract][Full Text] [Related]
14. [Significance of galenic preparations for luminal release of 5-aminosalicylic acid in human small intestinal lumen].
Keller J; Goebell H; Klotz U; Layer P
Med Klin (Munich); 1998 May; 93(5):294-9. PubMed ID: 9630813
[TBL] [Abstract][Full Text] [Related]
15. Anastomotic configuration and mucosal 5-aminosalicyclic acid (5-ASA) concentrations in patients with Crohn's disease: a GISC study. Gruppo Italiano per lo Studio del Colon e del Retto.
Frieri G; Pimpo MT; Palumbo G; Tonelli F; Annese V; Sturniolo GC; Andreoli A; Comberlato M; Corrao G; Caprilli R
Am J Gastroenterol; 2000 Jun; 95(6):1486-90. PubMed ID: 10894584
[TBL] [Abstract][Full Text] [Related]
16. Comparative absorption of 5-aminosalicylic acid (5-ASA) after administration of a 5-ASA enema and salazosulfapyridine (SASP) after an SASP suppository in Japanese volunteers.
Tokui K; Asai Y; Arakawa T; Matsumoto T; Nabeshima T
Biol Pharm Bull; 2002 Feb; 25(2):264-7. PubMed ID: 11853180
[TBL] [Abstract][Full Text] [Related]
17. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
18. Pharmaceutical approaches to colon targeted drug delivery systems.
Chourasia MK; Jain SK
J Pharm Pharm Sci; 2003; 6(1):33-66. PubMed ID: 12753729
[TBL] [Abstract][Full Text] [Related]
19. Application of a colon delivery capsule to 5-aminosalicylic acid and evaluation of the pharmacokinetic profile after oral administration to beagle dogs.
Takaya T; Sawada K; Suzuki H; Funaoka A; Matsuda K; Takada K
J Drug Target; 1997; 4(5):271-6. PubMed ID: 9169983
[TBL] [Abstract][Full Text] [Related]
20. [Drug therapy of chronic inflammatory intestinal diseases--current status of 5-aminosalicylic acid].
Schölmerich J; Gerok W
Wien Klin Wochenschr; 1986 Nov; 98(22):762-9. PubMed ID: 2880425
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
